Clinical Study

Impact of Body Mass Index on Surgical and Oncological Outcomes in Laparoscopic Total Mesorectal Excision for Locally Advanced Rectal Cancer after Neoadjuvant 5-Fluorouracil-Based Chemoradiotherapy

Table 1

Clinicopathological characteristics between nonobese and obese groups in locally advanced rectal cancer patients following nCRT.

CharacteristicsBMI < 25 ()BMI ≥ 25 () value

Sex0.085
 Male157 (63.1)47 (74.6)
 Female92 (36.9)16 (25.4)
Age (years)54.9 ± 12.054.7 ± 9.10.861
BMI (kg/m2)21.7 ± 2.226.9 ± 2.8<0.001
ASA score0.658
 1164 (65.9)45 (71.4)
 278 (31.3)17 (27.0)
 37 (2.8)1 (1.6)
Distance from the anal verge (cm)5.9 ± 2.15.9 ± 1.80.948
Gross type0.843
 Expanding56 (22.5)16 (25.4)
 Ulcering178 (71.5)44 (69.8)
 Infiltrating15 (6.0)3 (4.8)
Histopathology0.100
 Adenocarcinoma227 (91.2)53 (84.1)
 Mucinous or signet ring adenocarcinoma22 (8.8)10 (15.9)
Tumor differentiation0.196
 Well or moderately differentiated214 (85.9)50 (79.4)
 Poorly differentiated and othersa35 (14.1)13 (20.6)
Clinical T stage0.230
 T357 (22.9)19 (30.2)
 T4192 (77.1)44 (69.8)
Clinical N stage0.580
 N015 (6.0)5 (7.9)
 N+234 (94.0)58 (92.1)
Preoperative CEA level (ng/ml)0.650
 <5216 (86.7)56 (88.9)
 ≥533 (13.3)7 (11.1)

Data are expressed as number (%) or as median ± standard deviation, where appropriate. aIncluding mucinous and signet cell carcinoma. nCRT: neoadjuvant chemoradiotherapy; BMI: body mass index; ASA: American Society of Anesthesiology; CEA: carcinoembryonic antigen.